Academic Journal
Q1Pulmonary Therapy
About Pulmonary Therapy
Pulmonary Therapy is a scholarly journal published by Adis. SCImago 2025 lists it in Q1, with an SJR of 0.815 and H-index of 27.
Coverage: 2015-2026. Research categories: Respiratory Care (Q1); Pulmonary and Respiratory Medicine (Q2).
Verified field sources
- Journal Impact Factor: 3.0 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
- Impact Factor year: 2024 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2026-03-17. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Asthma and respiratory diseases; Chronic Obstructive Pulmonary Disease (COPD) Research; Inhalation and Respiratory Drug Delivery; Respiratory and Cough-Related Research; Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis; Respiratory Support and Mechanisms.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Advanced Pulmonary Drug Delivery Systems: A Narrative Review
Dil Afrose, Melika Valizadeh, Shailesh B. Kolekar, Mano J. Mathew et al.
2026-09-25 · DOI: 10.1007/s41030-026-00387-6Real-World Effectiveness of Mepolizumab Initiation in Treating Asthma and Concurrent Chronic Obstructive Pulmonary Disease in the US
Surya P. Bhatt, Ravi Kalhan, Shibing Yang, Guillaume Germain et al.
2026-09-24 · DOI: 10.1007/s41030-026-00381-yThe Global Initiative for Obstructive Sleep Apnea (GIFOSA): Rationale, Strategic Framework, and Call to Action
Sy Duong-Quy, Naricha Chirakalwasan, Tayard Desudchit, Stanley Yung-Chuan Liu et al.
2026-09-21 · DOI: 10.1007/s41030-026-00386-7Challenges and Burdens in Refractory Chronic Cough: Patients’ and Physicians’ Perspectives
Mandy Beadnell, José Canga Rodríguez, Ottilie Dotzenrod, Isadora Farrell et al.
2026-09-18 · DOI: 10.1007/s41030-026-00384-9Cough in Interstitial Lung Disease: Current Knowledge and Research Gaps
Giacomo Giulianelli, Serena Bellani, Gioele Castelli, Giordano Fiorentù et al.
2026-09-08 · DOI: 10.1007/s41030-026-00385-8Advanced Bronchoscopic Approaches to Peripheral Pulmonary Lesions: a Narrative Review of Current and Emerging Techniques
Richard Westley, Alberto Fantin, Ernesto Crisafulli, Rakesh Panchal et al.
2026-09 · DOI: 10.1007/s41030-026-00377-8Immunometabolic Modulation in Obese Asthma: How GLP-1 Receptor Agonists Could Influence Systemic and Pulmonary Immune Phenotypes
Helen O’Brien, Adam J. Byrne, Alessandro N. Franciosi, Marcus W. Butler et al.
2026-09 · DOI: 10.1007/s41030-026-00380-zIncidence of New Malignancies in Severe Asthma: Comparison of Real-World Patients Treated with Benralizumab, Other Biologics, or Non-biologics
Eileen O. Dareng, Trung N. Tran, Hannah Urbanski, Ryan Finch et al.
2026-09 · DOI: 10.1007/s41030-026-00379-6Bridging the Knowledge Gap: Transforming COPD Management Through Lessons from Asthma
Javier de Miguel-Díez, Francisco Javier Callejas-González, Marina Blanco-Aparicio, Borja G. Cosío et al.
2026-09 · DOI: 10.1007/s41030-026-00376-9The Genetic Architecture of Chronic Cough: From Sensory Hypersensitivity to Treatable Trait
Ran Dong, Mengru Zhang, Alyn H. Morice
2026-09 · DOI: 10.1007/s41030-026-00382-xInterstitial Lung Disease Induced by Monoclonal Antibodies for Psoriatic Arthritis, a Double Hit: A Case Report with a Literature and Clinical Trial Review
Gioele Castelli, Giordano Fiorentù, Giuseppe Maggioni, Serena Bellani et al.
2026-09 · DOI: 10.1007/s41030-026-00378-7A Review of Analgesic and Anaesthetic Approaches in Local Anaesthetic (Medical) Thoracoscopy
Jasandra Sutanto, Duneesha DeFonseka, Bernard Duysinx, Valentina Pinelli et al.
2026-09 · DOI: 10.1007/s41030-026-00373-yEfficacy and Safety of Brensocatib in Participants of Asian Race with Non-cystic Fibrosis Bronchiectasis: A Subgroup Analysis of the ASPEN Trial
Doreen Addrizzo-Harris, James D. Chalmers, Stefano Aliberti, Pierre-Régis Burgel et al.
2026-09 · DOI: 10.1007/s41030-026-00375-wRespiratory Support in Pediatric Critical and Near-Fatal Asthma: A Narrative Review
Long Xiang, Herng Lee Tan, Andrew Miller, Alexandre T. Rotta et al.
2026-09 · DOI: 10.1007/s41030-026-00374-xSarcoidosis: A Clinical Trials Perspective
Juan J. Zapata-Huizi, Manuela Herrera-Tamayo, Josmar J. Ríos-Poveda, Eli N. Pérez-Rodas et al.
2026-09 · DOI: 10.1007/s41030-026-00372-zEstimating the Underreporting of COVID-19 Burden in Selected Countries in Asia, Africa, the Middle East, and Latin America in the Post-pandemic Era
Carlos Fernando Mendoza, Julia Spinardi, Iustina Chirila, Claire Spencer et al.
2026-09 · DOI: 10.1007/s41030-026-00371-0COPD Biologics: Right Patient, Right Pathway, Right Time
Lydia J. Finney, Francesca M. Conway, Dheeraj K. Sethi
2026-09 · DOI: 10.1007/s41030-026-00370-1Summary of Research: Dupilumab for Chronic Obstructive Pulmonary Disease with Type 2 Inflammation: A Pooled Analysis of Two Phase 3, Randomised, Double-Blind, Placebo-Controlled Trials
Surya P. Bhatt, Klaus F. Rabe, Nicola A. Hanania, Claus F. Vogelmeier et al.
2026-09 · DOI: 10.1007/s41030-026-00361-2Destroyed Lungs and Surgical Management
Lihui Yu, Jingyu Chen
2026-09 · DOI: 10.1007/s41030-026-00369-8Global pMDI Use and the Potential Impact of European PFAS Legislation on Access to These Essential Inhaled Medications
Janwillem W. H. Kocks, Tim Harrison, John P. Bell, Andy Rignall et al.
2026-06 · DOI: 10.1007/s41030-026-00362-1Reviews
Community Reviews
Version History
October 4, 2026 at 9:04 pm
October 2, 2026